BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). (June 2017)